BridgeBio reported positive top-line results from its global Phase 3 Propel 3 trial of infigratinib in children with achondroplasia, the most common genetic form of dwarfism. The oral FGFR3 inhibitor met the primary endpoint, producing a statistically significant increase in annualized height velocity compared with placebo, and recorded favorable secondary growth measures, the company said. BridgeBio plans regulatory engagements and intends to pursue filings later this year; if approved, infigratinib would offer an oral alternative to injectable growth therapies. Analysts note the result intensifies competition with existing and imminent therapies from BioMarin and Ascendis and could reshape treatment access dynamics for pediatric patients with achondroplasia.